Hansa's €115 Million Out Licensing of Idefirix in Europe and MENA to SERB

May 19, 2026

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations or that of its affiliates or subsidiary companies. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

Conference Call: Agenda

May 19, 2026

Transaction Overview		**Renée Aguiar-Lucander** CEO
Financial Update		Evan Ballantyne CFO
Close and Q&A		Renée Aguiar-Lucander CEO

Transaction Background

SITUATION
European backdrop

- Significant market opportunity
- Fragmented markets with differing reimbursement, guidelines and organ allocation systems
- Substantial resource requirements to maximize market opportunity
- Limited leverage with a single, orphan product compared to a more diversified, complementary product portfolio

PROCESS
Strategic fit & resources

- Significant inbound interest from multiple potential partners
- Assessment focused on market presence, patient reach, value creation and long-term strategy
- Decision to partner with an experienced, larger European organization

OUTCOME
Out-licensing agreement

- Transformative €115 million deal validating franchise and market opportunity
- Greater regional scale and reach for patients in Europe
- Intention is to transfer relevant Hansa employees to SERB, subject to labor consultations
- Significantly improved cash runway with path to profitability - sharpened focus on U.S. launch and pipeline development

Transaction Overview

Transaction Scope

Exclusive out-licensing of Idefirix for transplantation in EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA to SERB

Transaction Financials

- **€110 million paid upfront**
- Upon **acceptance by EMA of filing for full approval**, additional payment of **€5 million**

Transition and Next Steps

- The transaction is subject to customary regulatory approvals, including foreign direct investment (FDI)
- Transfer of European MAH to SERB to be initiated immediately post-closing
- Hansa and SERB to focus on ensuring a smooth, well-coordinated handover

Partnership Responsibilities

SERB

- **Commercialization & medical affairs** across licensed territories from closing
- Post transfer of Marketing Authorization Holdership (MAH):
  - **Filing and obtaining full marketing authorization with EMA**
  - **Sponsorship** of **long-term PAES follow-up** and **paediatric study**

Hansa

- **PAES readout**
- Hansa to initiate **transfer of MAH** to SERB
- **Support SERB** in its EMA submission for full marketing authorization of Idefirix, and the EMA review process
- **Supply of Idefirix** to the licensed region

SERB at a Glance

- **Global specialty pharmaceutical company** with 25+ years of experience in rare diseases, rare medical emergencies and medical countermeasures
- Diversified portfolio in **Critical Care and Rare Disease** with >70 products
- **Direct presence in 18 countries**. Distribution footprint through >60 partnerships (~80 countries). More than 600 employees
- Long-standing relationships with health networks, governments, NGOs and patients
- Strong historical performance and long-term growth potential
- Proven reliable partner with strong track record to unlock full potential for all stakeholders
- Platform built to smoothly operate a wide range of lifesaving product globally
- Strong M&A track record

Select members of the executive team:

- Jérémie Urbain, Executive Chairman
- Vanessa Wolfeler, CEO
- Antoine Bernasconi, CCO, EU/International
- Vincent Sainte-Catherine, COO
- Arthur Pignot, Chief Strategy Officer
- Vignesh Rajah, Chief Medical Officer
- Flore Lapert, Head of EU, Commercial Operations

Transaction Timeline

Illustrative Transaction Timeline

- **Signing**
- FDI review (expected 30-60 days)
- Start of employee consultations
- **Closing**
  - €110 million upfront received from SERB
  - Commercial & medical affairs responsibility transferred to SERB
  - Hansa initiates Market Authorization Holdership (MAH) transfer request
- **MAH transferred**
  - SERB responsible for PAES long-term follow-up and paediatric study
  - SERB files for EMA full approval
  - Employee transfer following consultation process

Post Announcement and Before Closing

- Business as usual
- No impact on Hansa organizational or commercial responsibilities
- Readout of PAES and preparation of filing for EMA full approval
- Focus on setting up a smooth, well-coordinated handover post-closing
- Employee consultation processes launched across the territory
- Preparation for transfer of clinical trials (PAES long-term follow-up and paediatric) to SERB post transfer of MAH

Post Closing and Going Forward

- Responsibility for European commercialization related activities transferred to SERB
- Hansa to supply Idefirix to licensed territory
- Hansa to fully support SERB regarding filing with EMA for full approval, and subsequent review process
- At transfer of MAH to SERB, transfer of sponsorship of related clinical trials
- Alliance management structure in place with focus on maximizing long-term benefit for patients and stakeholders

Hansa Focus Going Forward

Robust Preparations for US Launch

- ✓ Leadership team complete
- ✓ Field presence strengthened
- ✓ Pricing Market research conducted
- ConfIdeS data oral presentation at ATC in June
- Comprehensive pre-launch plan being executed

Clinical Development of HNSA-5487 in GBS

- Interactions with FDA regarding clinical development program
- CRO selected and preparation activities started
- Target to initiate clinical development program by YE 2026

Other Key Activities

- FDA BLA review process
- Continue to drive early pipeline
- BD focus on exploring potential partnerships across gene therapy and other potential areas

Key Takeaways

- **€110 million upfront consideration** for out licensing of Idefirix in Europe, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA. Additional **€5 million** payment upon EMA acceptance of submission for conversion from conditional to full approval
- Substantial **non-dilutive financing** ensuring robust US launch and **path to profitability**, subject to US approval
- Signing to closing period: Focus on **business as usual** – parties to make preparations to ensuring a smooth handover
- **Post closing**
  - Optimizing **patient access** to Idefirix backed by an experienced and strong European business
  - **Hansa to submit request to EMA to transfer MAH to SERB;** upon transfer, SERB to take over responsibility for filing for full approval and subsequent approval process, supported by Hansa, as well as sponsorship for clinical trials (PAES long-term follow-up and paediatric trial)
- **Alliance management structure** put in place to ensure smooth handover and consistent support over the long term
- Hansa to continue to **supply Idefirix to the Territory**

Conference Call: Agenda

May 19, 2026

Transaction Overview		Renée Aguiar-Lucander CEO
Financial Update		**Evan Ballantyne** CFO
Close and Q&A		Renée Aguiar-Lucander CEO

Estimated Financial Impact of Transaction

Cash Position

- Transaction (upfront €110M or 1.3 BSEK) significantly increases Hansa's cash position
- Pro forma cash based on Q1 2026 cash on hand 1.9 BSEK
- Upon EMA acceptance of filing for approval; payment of €5M (~55 MSEK)

Reduced Cost Base

- Improves **Hansa's cost** base in 2H 2026 by up to 50 MSEK. Savings in 2027 up to 150 MSEK compared to budget
- Impact from:
  - Reduced Medical Affairs & Commercial costs, subject to consultation
  - Reduced R&D costs (PAES long-term follow-up and paediatric study transferred to SERB post MAH transfer)

Cash Runway

- Out licensing agreement provides path to **profitability, subject to US approval**
- Part of proceeds used to de-lever the company. US$15M payable at closing to Novaquest with $10 million offsetting the mid 2027 payment and the balance going towards 2028 and 2029 payments. In addition, a $3M lien release fee will be payable to NovaQuest at closing.

Pro Forma Q1 2026 Cash
with Out Licensing Agreement*



Before payment of fees and debt repayments

Euro to US$ 1.16
Euro to SEK 10.99
US$ to SEK 9.45

Conference Call: Agenda

May 19, 2026



Transaction Overview		Renée Aguiar-Lucander CEO
Financial Update		Evan Ballantyne Chief Financial Officer
Close and Q&A		**Renée Aguiar-Lucander** CEO

Hansa Today

- One year in – **structural changes across the business implemented**. Substantial improvements achieved with regards to financial stability, runway, pipeline strategy, internal expertise and experience.
- **Positive outlook for the year** reflecting several key data related milestones and potential US approval.
- **Transformative out licensing** deal in Europe:
  - Maximizing patient access to Idefirix backed by an experienced and strong European business**.**
  - **Non-dilutive financing ensuring** robust US launch and path to profitability, subject to US approval
- **Release of PAES data in Q2** will provide a basis for productive interactions with physicians across the region and significantly increase clinical knowledge and confidence among KOLs which should positively impact uptake.
- **ConfIdeS Phase 3 data to be presented at ATC in June** – first time that substantial, controlled clinical data is available to characterize imlifidase efficacy and safety.
- **Capital Markets Day June 25, 2026** at St Regis Hotel in New York and virtually.

Hansa Biopharma Capital Markets Day

Featuring Key European and US KOLs

Thursday 25th of June, 2026 from 9:00 AM to 12:00 PM EDT

Location:

- **In-Person:** The St. Regis Hotel New York, U.S.
- **Virtual:** Live webcast

In-Person Sign-up and Webcast Access:

Hansa Biopharma Capital Markets Day

More details and full agenda to follow

Q&A